Physician profile
Peter A Santisi
NPI 1619083219
$6,950.21
in general payments reported to CMS, 2019-2025
18 companies · $739 in 2025
The $739 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,427 · 2020: $653 · 2021: $896 · 2022: $1,073 · 2023: $789 · 2024: $373 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,881 · Consulting Fee: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,881.02 |
| Consulting Fee | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,977.46 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,237.55 | 2019-2020 | |
| Allergan, INC. | $875.21 | 2019-2021 | |
| Abbvie INC. | $723.42 | 2022-2025 | Alphagan P, Vuity |
| Alcon Vision LLC | $679.42 | 2019-2025 | Clareon, Precision7, Tryptyr |
| Sight Sciences, INC. | $210.88 | 2020-2021 | |
| Visionix USA, INC | $177.19 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $149.95 | 2022-2023 | Acuvue |
| Optovue, INC. | $144.22 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $136.67 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $121.44 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $104.46 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $100.00 | 2022-2023 | Tyrvaya |
| Glaukos Corporation | $94.20 | 2020 | |
| Lombart Brothers, INC. | $68.69 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $58.59 | 2021 | |
| Lumibird Medical INC. | $53.88 | 2019 | |
| Bausch & Lomb Americas INC. | $36.98 | 2024 | Infuse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Santisi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.